Description
About Roivant Sciences
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize medicines and technologies. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 8 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. In addition to a robust clinical stage pipeline, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
We embrace diversity across all dimensions and levels of the organization, and we strive to ensure every employee is supported in reaching their full potential. We hire motivated people with diverse backgrounds, identities, experiences and skillsets. We are committed to fostering an inclusive culture where all employees feel valued, respected and empowered to create value for patients.
To learn more about our story and company culture, please visit us at https://roivant.com/
About the Rotational Analyst Program
Our two-year Rotational Analyst Program begins in July 2027. It offers recent college graduates the opportunity to complete four (4) six-month rotations across different teams and functions, including our portfolio of Vants. The aim of this program is to attract and develop future leaders across the Roivant family by accelerating the development of talent. From day one, analysts will own projects and have opportunities to make a meaningful impact. Now in its seventh year, Rotational Analysts have taken on demanding projects across a wide range of functions at Roivant and the Vants.
Sample Projects Include:
- Investments: Evaluating in-licensing opportunities to expand Roivant’s portfolio of life changing medicines
- Research and Development: Performing literature reviews to identify indication expansion opportunities in support of Vants
- Vants: Developing strategies to accelerate clinical trial recruitment
- Strategic Finance: Creating an investor deck, in partnership with key executives, for a Phase 3 clinical trial readout
Each year, graduates of our Rotational Analyst Program pursue exciting opportunities as full-time employees at Roivant or our Vants. Beyond the Roivant portfolio, RAs have gone on to pursue higher education at top universities.
Roivant is a Fast Company Best Workplace for Innovators, with the Rotational Analyst Program recognized as a standout among Science and Technology firms.
About You
We believe our employees are our most important asset. Our goal is to identify top talent with potential to develop into future leaders across our business. We prioritize intellect and entrepreneurial verve. We offer a fast-paced environment that values work ethic, analytical rigor, collaboration, and creative thinking. At Roivant, we will give you the resources and freedom to tackle some of the most important and challenging problems in healthcare. If you find that exciting, we want to work with you. Below, we’ve listed some preferred characteristics and requirements for our incoming Rotational Analysts. If this sounds like you, please apply today!
Preferred Skills & Characteristics
- Ambitious & Driven. Passionate about Roivant’s mission to improve health by rapidly delivering innovative medicines to patients, and curious about the intersection between science and technology.
- Curious & Analytical. Asks sharp questions and digs into data to find answers; superior verbal and written communication skills, with the ability to translate complex concepts into clear, concise recommendations.
- Self-Directed. Independently capable of seeking information, solving conceptual problems, coordinating across teams, and delivering results in challenging situations. Hungry to get things done with minimal direction. Thrives in ambiguity.
- Conscientious & Detail Oriented. Strong multi-tasking, organizational, and project planning skills, and a demonstrated ability to meet aggressive deadlines.
- Impatient & Scrappy. Ability to get things done while quickly adapting to a rapidly changing environment; demonstrated capacity for creative problem-solving, a can-do attitude to overcome any obstacle, and a relentless, persistent bias for action.
Qualifications
- Enrolled in a 4-year undergraduate university in the United States with an expected graduation date between December 2026 and June 2027, as this program begins July 2027.
- Currently pursuing an undergraduate degree in the life sciences, business, economics, or a related quantitative field (e.g., Biology, Chemistry, Biochemistry, Economics, Finance, Data Science, Public Health), with demonstrated interest or experience in healthcare, biotech, or the life sciences.
Requirements:
- Track record of academic excellence; GPA of 3.5 or higher.
- Willingness to relocate to New York, NY.
- Authorization to work in the U.S. This role is not eligible for visa sponsorship including STEM-OPT.
The expected base salary for the role is $100,000 per year at the commencement of employment.
Base salary if hired is only part of the total compensation package, which, depending on the position, may also include other components such as discretionary bonuses, equity, and Company-sponsored benefit programs.
This position is at-will and Roivant reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance and business and market conditions.
Roivant Sciences provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
We will not accept unsolicited resumes nor outreach from agencies. Please do not send agency resumes to our website or Roivant Sciences and affiliated employees.
Similar jobs
Est. 142,500 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 132,500 USD
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiar…
Est. 175,000 USD
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiar…
Est. 155,000 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 175,000 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 158,500 USD
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiar…
Est. 320,000 USD
Associate – New Ventures, Asset Selection RTW Investments RTW Investments, LP (“RTW”) is a global, full life-cycle investment and innovation firm dedicated to solving the most challenging, unmet patient needs. We are foc…
Est. 209,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 261,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 195,000 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 199,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 221,450 USD
Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on In 2015, we pioneered a “moneyball for biotech”…
Est. 330,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 248,800 USD
Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on In 2015, we pioneered a “moneyball for biotech”…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 209,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 226,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 209,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 160,000 USD
Imagine if you had the skills, knowledge, and teammates to both understand the root of the world’s most pressing problems and build the technologies and companies best positioned to solve them. RA Capital has done exactl…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 111,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 330,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 371,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 226,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…